Announcements
On 6 June 2017, the World Health Organization (WHO) published updates to its ‘Essential Medicines List’ (EML). Read more here.

Extended deadline (from 1 July to 31 July) 2017 for call to submit papers on effectiveness and cost-effectiveness of screening and prevention of infectious diseases among newly arrived migrants in Europe. Read more here.

Eurosurveillance is on the updated list of the Directory of Open Access Journals and in the SHERPA/RoMEO database. Read more here.

Follow Eurosurveillance on Twitter: @Eurosurveillanc


In this issue


Home Eurosurveillance Edition  2013: Volume 18/ Issue 16 Article 4
Back to Table of Contents
Previous Download (pdf)
Next

Eurosurveillance, Volume 18, Issue 16, 18 April 2013
News
WHO revised definitions and reporting framework for tuberculosis
  1. European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden

Citation style for this article: Eurosurveillance editorial team. WHO revised definitions and reporting framework for tuberculosis. Euro Surveill. 2013;18(16):pii=20455. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20455

On 15 April 2013, the World Health Organization (WHO) launched the revision of the ‘Definitions and reporting framework for tuberculosis’ (2013 revision) [1]. This document updates the previous WHO standard case definitions for tuberculosis (TB) and drug-resistant TB, the categories used to assign outcomes and the standard reporting framework for TB [2-4].

The standardisation of definitions and reporting structures has permitted comparability of indicators of performance between national TB control programmes and over time. In the course of the 2013 revision, efforts were made to maintain continuity in the surveillance parameters while also ensuring that the new framework captures information about bacteriologically-confirmed TB cases and drug-resistant strains detected using novel, WHO-endorsed molecular testing methodologies. The treatment outcome definitions of ‘cured’ and ‘treatment failed’ for rifampicin-resistant TB (RR-TB) and multidrug-resistant TB (MDR-TB) patients needed simplification to allow their wider application to patients still on treatment. In addition, the judgemental terms ‘defaulter’ and ’TB suspect’ have now been replaced by ’lost to follow-up’ and ’presumptive TB’ respectively.

The recording and reporting forms for paper-based systems were also updated to bring them in line with the revised case and treatment outcome definitions. Countries using electronic systems for TB recording and reporting are expected to adapt their software to incorporate the revised case and outcome definitions and to produce the indicator reports along the same lines. Nonetheless, the forms, registers and reports are intended to be illustrative rather than prescriptive and should serve to demonstrate how a minimum dataset for recording and reporting could be compiled. Each country will have its own particular requirements and will need to modify the forms, registers and reports to suit its needs. While the revised definitions are intended for immediate application, the process for their full adoption will need to factor in sufficient time to allow for effective communication, training, supervision, revision of procedures and policies, and the adaptation of information systems.


References

  1. World Health Organization (WHO). Definitions and reporting framework for tuberculosis. Geneva: WHO. 15 Apr 2013. Available from: http://apps.who.int/iris/bitstream/10665/79199/1/9789241505345_eng.pdf
  2. World Health Organization (WHO). Guidelines for treatment of tuberculosis, 4th ed. Geneva: WHO. 2009. Available from: http://whqlibdoc.who.int/publications/2010/9789241547833_eng.pdf
  3. World Health Organization (WHO). Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. Geneva: WHO. 2008. Available from: http://whqlibdoc.who.int/publications/2008/9789241547581_eng.pdf
  4. World Health Organization (WHO). Revised TB recording and reporting forms and registers - version 2006. Geneva: WHO. 2006. Available from: http://www.who.int/tb/dots/r_and_r_forms/en/


Back to Table of Contents
Previous Download (pdf)
Next

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN] - ©2007-2016. All rights reserved
 

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.